Clinical significance of CD 163+ tumor‐associated macrophages in patients with adult T‐cell leukemia/lymphoma
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
In several malignant tumors including lymphoma, macrophages that infiltrate tumor tissues are called tumor‐associated macrophages (TAM s). We discovered that TAM s, especially the CD 163+ alternatively activated phenotype (M2), were closely involved with progression of adult T‐cell leukemia/lymphoma (ATLL). We used CD 68 (a pan‐macrophage marker) and CD 163 (an M2 marker) to immunostain 58 ATLL samples. Statistical analyses showed that a high number of CD 68+ TAM s and an increased percentage of CD 163+ cells among the TAM s were associated with a worse clinical prognosis; multivariate analysis indicated that the percentage of CD 163+ cells was an independent prognostic factor. We also carried out in vitro coculture experiments with ATLL cell lines (ATN‐1 and TL‐Mor) and monocyte‐derived macrophages and found that direct coculture with M2 macrophages significantly increased BrdU incorporation into ATLL cell lines. A cytokine array analysis showed that macrophage‐derived soluble factors including C5a, tumor necrosis factor‐α, growth‐related oncogene‐α, CCL 1/I‐309, and interleukin‐6 stimulated ATLL cell lines. CD 163 expression in macrophages was strongly induced by direct contact with ATN‐1 cells, and downregulation of CD 163 in macrophages significantly suppressed growth of cocultured ATN‐1 cells. These results suggest that interaction between M2 macrophages and lymphoma cells may be an appropriate target in treatment of patients with ATLL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MANTOVANI, A., SOZZANI, S., LOCATI, M., ALLAVENA, P., & SICA, A. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02302-5 · Cited by 5,528
Bingle, L., Brown, N. J., & Lewis, C. E. (2002) · The Journal of Pathology · doi:10.1002/path.1027 · Cited by 2,022
Shimoyama, M., & members of The Lymphoma Study Group (1984–87) (1991) · British Journal of Haematology · doi:10.1111/j.1365-2141.1991.tb08051.x · Cited by 1,608
Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma
Steidl, C., Lee, T., Shah, S. P., Farinha, P., Han, G., Nayar, T., Delaney, A., Jones, S. J., Iqbal, J., Weisenburger, D. D., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0905680 · Cited by 1,262
Macrophage polarization in tumour progression
Sica, A., Larghi, P., Mancino, A., Rubino, L., Porta, C., Totaro, M. G., Rimoldi, M., Biswas, S. K., Allavena, P., & Mantovani, A. (2008) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2008.03.004 · Cited by 1,241
“Re-educating” tumor-associated macrophages by targeting NF-κB
Hagemann, T., Lawrence, T., McNeish, I., Charles, K. A., Kulbe, H., Thompson, R. G., Robinson, S. C., & Balkwill, F. R. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080108 · Cited by 792
Possible involvement of the M2 anti‐inflammatory macrophage phenotype in growth of human gliomas
Komohara, Y., Ohnishi, K., Kuratsu, J., & Takeya, M. (2008) · The Journal of Pathology · doi:10.1002/path.2370 · Cited by 738
Self-citationBode, J. G., Albrecht, U., Häussinger, D., Heinrich, P. C., & Schaper, F. (2012) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2011.09.008 · Cited by 379
Scavenger receptors: role in innate immunity and microbial pathogenesis
Areschoug, T., & Gordon, S. (2009) · Cellular Microbiology · doi:10.1111/j.1462-5822.2009.01326.x · Cited by 317
Long-term study of indolent adult T-cell leukemia-lymphoma
Takasaki, Y., Iwanaga, M., Imaizumi, Y., Tawara, M., Joh, T., Kohno, T., Yamada, Y., Kamihira, S., Ikeda, S., Miyazaki, Y., et al. (2010) · Blood · doi:10.1182/blood-2009-09-242347 · Cited by 180
Cited by
An Immune Atlas of Clear Cell Renal Cell Carcinoma
Chevrier, S., Levine, J. H., Zanotelli, V. R. T., Silina, K., Schulz, D., Bacac, M., Ries, C. H., Ailles, L., Jewett, M. A. S., Moch, H., et al. (2017) · Cell · doi:10.1016/j.cell.2017.04.016 · Cited by 1,004
Tumor-associated macrophages: Potential therapeutic targets for anti-cancer therapy
Komohara, Y., Fujiwara, Y., Ohnishi, K., & Takeya, M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.11.009 · Cited by 612
Self-citationClinical significance of macrophage heterogeneity in human malignant tumors
Komohara, Y., Jinushi, M., & Takeya, M. (2014) · Cancer Science · doi:10.1111/cas.12314 · Cited by 551
Self-citationYang, Q., Guo, N., Zhou, Y., Chen, J., Wei, Q., & Han, M. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.04.004 · Cited by 471
Major pathways involved in macrophage polarization in cancer
Kerneur, C., Cano, C. E., & Olive, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1026954 · Cited by 337
Metadata
- Authors
- Komohara, Y., Niino, D., Saito, Y., Ohnishi, K., Horlad, H., Ohshima, K., & Takeya, M.
- Venue
- Cancer Science
- Publisher
- Wiley
- Published
- 2013-05-09
- Volume
- 104
- Issue
- 7
- Pages
- 945-951
- ISSN
- 1347-9032 (ISSN-L)
- 1349-7006
- OpenAlex
- W2040589111
- Cited by
- 113
- References
- 10
- FWCI
- 4.72
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.